Van Etten JL, et al. – Researchers wanted to figure out whether targeting a single alternative polyadenylation site coordinately blocked expression of androgen receptor mRNA splice variants in prostate cancer. Based on the data, they supported the development of new therapies targeting the polyadenylation signal in androgen receptor (AR) intron 3 as a strategy to prevent expression of a broad array of AR variants in castration resistant prostate cancer (CRPC).